BREAKING NEWS

BREAKING NEWS

Bayer pharma growth tempered by weak agriculture, consumer units

Now Reading:

Bayer pharma growth tempered by weak agriculture, consumer units

Text size Aa Aa

FRANKFURT (Reuters) – Germany’s Bayer <BAYGn.DE>, which is buying U.S. seeds company Monsanto <MON.N>, posted a 4 percent gain in quarterly underlying core earnings on growth in pharmaceutical sales but held back by weak consumer healthcare and crop chemicals businesses. Bayer’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the third quarter came in at 2.20 billion euros ($2.60 billion), slightly higher than the average forecast by analysts of 2.12 billion euros, helped by continued growth in prescriptions for anti-clotting drug Xarelto. Bayer said it continues to expect 2017 EBITDA before special items to come in slightly above last year’s level.

(Reporting by Ludwig Burger; Editing by Maria Sheahan)
euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.